278 related articles for article (PubMed ID: 24622516)
1. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans.
Spencer AG; Labonte ED; Rosenbaum DP; Plato CF; Carreras CW; Leadbetter MR; Kozuka K; Kohler J; Koo-McCoy S; He L; Bell N; Tabora J; Joly KM; Navre M; Jacobs JW; Charmot D
Sci Transl Med; 2014 Mar; 6(227):227ra36. PubMed ID: 24622516
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD.
Labonté ED; Carreras CW; Leadbetter MR; Kozuka K; Kohler J; Koo-McCoy S; He L; Dy E; Black D; Zhong Z; Langsetmo I; Spencer AG; Bell N; Deshpande D; Navre M; Lewis JG; Jacobs JW; Charmot D
J Am Soc Nephrol; 2015 May; 26(5):1138-49. PubMed ID: 25404658
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.
Johansson S; Rosenbaum DP; Knutsson M; Leonsson-Zachrisson M
Clin Exp Nephrol; 2017 Jun; 21(3):407-416. PubMed ID: 27368672
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats.
Wu-Wong JR; Chen YW; Wessale JL
Am J Physiol Renal Physiol; 2015 Feb; 308(4):F309-19. PubMed ID: 25503724
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.
King AJ; Siegel M; He Y; Nie B; Wang J; Koo-McCoy S; Minassian NA; Jafri Q; Pan D; Kohler J; Kumaraswamy P; Kozuka K; Lewis JG; Dragoli D; Rosenbaum DP; O'Neill D; Plain A; Greasley PJ; Jönsson-Rylander AC; Karlsson D; Behrendt M; Strömstedt M; Ryden-Bergsten T; Knöpfel T; Pastor Arroyo EM; Hernando N; Marks J; Donowitz M; Wagner CA; Alexander RT; Caldwell JS
Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158152
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats.
King AJ; Kohler J; Fung C; Jiang Z; Quach A; Kumaraswamy P; Chertow GM; Rosenbaum DP
Am J Physiol Renal Physiol; 2021 Jan; 320(1):F133-F144. PubMed ID: 33283643
[TBL] [Abstract][Full Text] [Related]
7. Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome.
Zielińska M; Wasilewski A; Fichna J
Expert Opin Investig Drugs; 2015; 24(8):1093-9. PubMed ID: 26065434
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers.
Rosenbaum DP; Yan A; Jacobs JW
Clin Drug Investig; 2018 Apr; 38(4):341-351. PubMed ID: 29363027
[TBL] [Abstract][Full Text] [Related]
9. Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study.
Johansson SA; Knutsson M; Leonsson-Zachrisson M; Rosenbaum DP
Clin Pharmacol Drug Dev; 2017 Sep; 6(5):457-465. PubMed ID: 28339149
[TBL] [Abstract][Full Text] [Related]
10. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
Chey WD; Lembo AJ; Rosenbaum DP
Am J Gastroenterol; 2017 May; 112(5):763-774. PubMed ID: 28244495
[TBL] [Abstract][Full Text] [Related]
11. New functions and roles of the Na
Dominguez Rieg JA; Rieg T
Pflugers Arch; 2024 Apr; 476(4):505-516. PubMed ID: 38448727
[TBL] [Abstract][Full Text] [Related]
12. Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.
Block GA; Rosenbaum DP; Leonsson-Zachrisson M; Stefansson BV; Rydén-Bergsten T; Greasley PJ; Johansson SA; Knutsson M; Carlsson BC
Clin J Am Soc Nephrol; 2016 Sep; 11(9):1597-1605. PubMed ID: 27340281
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders.
Johansson S; Leonsson-Zachrisson M; Knutsson M; Spencer AG; Labonté ED; Deshpande D; Kohler J; Kozuka K; Charmot D; Rosenbaum DP
Clin Pharmacol Drug Dev; 2017 Sep; 6(5):448-456. PubMed ID: 27654985
[TBL] [Abstract][Full Text] [Related]
14. Reducing blood pressure in SHR with enalapril provokes redistribution of NHE3, NaPi2, and NCC and decreases NaPi2 and ACE abundance.
Yang LE; Leong PK; McDonough AA
Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1197-208. PubMed ID: 17652375
[TBL] [Abstract][Full Text] [Related]
15. The Myth of Water and Salt: From Aquaretics to Tenapanor.
Visconti L; Cernaro V; Calimeri S; Lacquaniti A; De Gregorio F; Ricciardi CA; Lacava V; Santoro D; Buemi M
J Ren Nutr; 2018 Mar; 28(2):73-82. PubMed ID: 29146141
[TBL] [Abstract][Full Text] [Related]
16. Effects of enalapril and hydrochlorothiazide on the salt-induced cardiac and renal hypertrophy in normotensive rats.
Mervaala EM; Laakso J; Vapaatalo H; Karppanen H
Naunyn Schmiedebergs Arch Pharmacol; 1994 Oct; 350(4):416-25. PubMed ID: 7845479
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of NHE3-mediated Sodium Absorption in the Gut Reduced Cardiac End-organ Damage Without Deteriorating Renal Function in Obese Spontaneously Hypertensive Rats.
Linz B; Hohl M; Reil JC; Böhm M; Linz D
J Cardiovasc Pharmacol; 2016 Mar; 67(3):225-31. PubMed ID: 26727380
[TBL] [Abstract][Full Text] [Related]
18. Enalapril induces regression of cardiac hypertrophy and normalization of pHi regulatory mechanisms.
Ennis IL; Alvarez BV; Camilión de Hurtado MC; Cingolani HE
Hypertension; 1998 Apr; 31(4):961-7. PubMed ID: 9535421
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic inhibition of intestinal sodium uptake: a gut centric approach to sodium management.
Spencer AG; Greasley PJ
Curr Opin Nephrol Hypertens; 2015 Sep; 24(5):410-6. PubMed ID: 26197202
[TBL] [Abstract][Full Text] [Related]
20. Na
Charoenphandhu N; Kraidith K; Lertsuwan K; Sripong C; Suntornsaratoon P; Svasti S; Krishnamra N; Wongdee K
Mol Cell Biochem; 2017 Mar; 427(1-2):201-208. PubMed ID: 27995414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
